Karyopharm Therapeutics Inc.KPTINASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank57
3Y CAGR-5.5%
5Y CAGR-3.6%
Year-over-Year Change
Research and development spending
3Y CAGR
-5.5%/yr
vs -2.0%/yr prior
5Y CAGR
-3.6%/yr
Consistent
Acceleration
-3.4pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $125.62M | -12.3% |
| 2024 | $143.23M | +3.2% |
| 2023 | $138.75M | -6.7% |
| 2022 | $148.66M | -7.6% |
| 2021 | $160.84M | +6.6% |
| 2020 | $150.81M | +23.3% |
| 2019 | $122.34M | -24.2% |
| 2018 | $161.37M | +50.4% |
| 2017 | $107.27M | +23.4% |
| 2016 | $86.94M | - |